In particular, Scartozzi et al. in the ALICE-1 study [11] and Faloppi et al. in the ALICE-2 study [12] showed that SNPs in the VEGF-A, VEGF-C, and HIF-1α genes were independent factors influencing PFS and OS in HCC patients receiving sorafenib. Here, VEGFC is linked to hepatocellular carcinoma.